Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.
Chau Dang, MD
Advertisement
Articles by Chau Dang, MD
Chau Dang, MD, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.
Chau Dang, MD, discusses the APHINITY trial, which explored the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive breast cancer.
Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as a combination treatment for patients with HER2-positive breast cancer.
Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the significance of MYL-1401O, a proposed biosimilar of trastuzumab, as a potential treatment for patients with HER2-positive metastatic breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates
5